# Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer

> **NCT04395612** · PHASE2 · UNKNOWN · sponsor: **Chongqing University Cancer Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** niraparib combined with brivanib
- **DRUG:** niraparib combined with toripalimab

## Key facts

- **NCT ID:** NCT04395612
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-08
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04395612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04395612, "Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04395612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*